Skip to main content
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MIST ISIN · USU6005B1045 LEI · 549300P43IPGW3Q3Y026 US Manufacturing
Open in API
Filings indexed 346 across all filing types
Latest filing 2026-05-13 Capital/Financing Update
Country US United States of America
Listing US MIST

About Milestone Pharmaceuticals Inc.

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company's lead investigational product is etripamil, a novel, fast-acting calcium channel blocker delivered as a nasal spray. This formulation is designed for patient self-administration to terminate episodes of certain heart rhythm disturbances outside of a hospital or emergency department setting. The primary indications under investigation for etripamil are paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to address unmet needs for acute, at-home treatment of these episodic conditions.

Recent filings

Filing Released Lang Actions
S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Capital/Financing Update Classification · 85% confidence The document is a Form S-3 registration statement filed with the SEC, containing the full prospectus for a shelf offering of up to $300 million of common shares, preferred shares, debt securities and warrants. This is clearly a financing activity—a detailed prospectus for a securities offering—rather than a financial report, proxy, or regulatory announcement. Therefore, it best fits the “Capital/Financing Update” category (Code: CAP).
2026-05-13 English
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K current report under the Securities Exchange Act, specifically Item 2.02 “Results of Operations and Financial Condition,” which states that the company issued a press release (Exhibit 99.1) announcing first‐quarter results. The 8‐K does not include the actual financial data but merely furnishes the press release as an exhibit. Per the “menu vs meal” rule, this very short filing that announces and attaches a report qualifies as a Report Publication Announcement rather than the report itself or an earnings release. Therefore, it should be classified as RPA.
2026-05-13 English
10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)
Major Shareholding Notification
2026-03-26 English
3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
Director's Dealing
2026-03-23 English
8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 20, 2026, by Milestone Pharmaceuticals Inc. It announces the issuance of a press release regarding financial results for the fourth quarter and fiscal year ended December 31, 2025. The document includes a reference to the press release as Exhibit 99.1 and explicitly states that the information is furnished and not filed, indicating it is an announcement rather than the full financial report itself. The length of the document is 4272 characters, which is relatively short and consistent with a current report filing. The content focuses on announcing financial results and a commercial update but does not contain detailed financial statements or substantive financial data. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for SEC current reports (Form 8-K) that announce events or press releases but do not contain full financial reports or detailed data.
2026-03-20 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.